- Home
- NTHI vs ALLO Comparison
NTHI vs ALLO Comparison
Compare NTHI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTHI
- ALLO
- Stock Information
- Founded
- NTHI 2008
- ALLO 2017
- Country
- NTHI United States
- ALLO United States
- Employees
- NTHI N/A
- ALLO N/A
- Industry
- NTHI Biotechnology: Pharmaceutical Preparations
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTHI Health Care
- ALLO Health Care
- Exchange
- NTHI Nasdaq
- ALLO Nasdaq
- Market Cap
- NTHI 211.9M
- ALLO 252.9M
- IPO Year
- NTHI N/A
- ALLO 2018
- Fundamental
- Price
- NTHI $10.10
- ALLO $1.28
- Analyst Decision
- NTHI
- ALLO Buy
- Analyst Count
- NTHI 0
- ALLO 12
- Target Price
- NTHI N/A
- ALLO $8.80
- AVG Volume (30 Days)
- NTHI 42.8K
- ALLO 2.9M
- Earning Date
- NTHI 11-19-2025
- ALLO 11-06-2025
- Dividend Yield
- NTHI N/A
- ALLO N/A
- EPS Growth
- NTHI N/A
- ALLO N/A
- EPS
- NTHI N/A
- ALLO N/A
- Revenue
- NTHI $59,990.00
- ALLO N/A
- Revenue This Year
- NTHI N/A
- ALLO N/A
- Revenue Next Year
- NTHI N/A
- ALLO $100.00
- P/E Ratio
- NTHI N/A
- ALLO N/A
- Revenue Growth
- NTHI N/A
- ALLO N/A
- 52 Week Low
- NTHI $3.20
- ALLO $0.86
- 52 Week High
- NTHI $25.00
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- NTHI N/A
- ALLO 49.56
- Support Level
- NTHI N/A
- ALLO $1.21
- Resistance Level
- NTHI N/A
- ALLO $1.31
- Average True Range (ATR)
- NTHI 0.00
- ALLO 0.07
- MACD
- NTHI 0.00
- ALLO -0.01
- Stochastic Oscillator
- NTHI 0.00
- ALLO 26.39
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.